Tag: pharmaceutical industry
-

Viatris and Opus’ Ryzumvi Wins FDA Approval for Adult Presbyopia
Ryzumvi wins FDA approval for adult presbyopia. Explore its pupil-reducing mechanism, Phase 3 results and the commercial challenges facing Viatris and Opus Genetics.
-

Roche’s Enspryng Wins FDA Approval for Thyroid Eye Disease
Roche’s Enspryng wins FDA approval for adult thyroid eye disease. Explore its IL-6 receptor blockade, antibody recycling technology, mixed Phase 3 results and the commercial implications of at-home treatment.
-

ImmunityBio’s Anktiva Wins FDA Expansion in Bladder Cancer
The FDA expanded ImmunityBio’s Anktiva plus BCG to high-grade papillary-only bladder cancer. The decision extends existing CIS efficacy evidence to a related patient population, broadening the IL-15 receptor agonist’s approved role.
-

BMS’ RYZ101 Meets Phase 3 Endpoint in Neuroendocrine Tumors
BMS’ RYZ101 met its Phase 3 progression-free survival endpoint in neuroendocrine tumors after lutetium-177 therapy. Detailed efficacy and safety data remain pending.
-

Teva’s Weltruza Wins FDA Approval for Monthly Schizophrenia Treatment
Teva’s Weltruza wins FDA approval for monthly schizophrenia treatment. Medincell’s delivery technology reduces administration burden, while olanzapine’s metabolic risks remain.
-

Viatris to Acquire Pacira for $1.65B in Non-Opioid Pain Push
Viatris agreed to acquire Pacira BioSciences for $1.65 billion, adding Exparel, Zilretta and an established U.S. specialty platform. The deal advances Viatris’ shift toward innovative medicines but also introduces patent, generic competition and integration risks.
-

Cerevance Solengepras Meets Phase 3 Endpoint in Parkinson’s Disease
Cerevance’s GPR6 inverse agonist solengepras reduced daily OFF time by 0.61 hours versus placebo in the Phase 3 ARISE trial.
-

Vaxcyte’s VAX-31 Meets Phase 3 Endpoints Versus Prevnar 20 and Capvaxive
Vaxcyte’s VAX-31 met all prespecified primary endpoints in the Phase 3 OPUS-1 trial, supporting its potential as a broader adult pneumococcal vaccine. The candidate includes all 20 Prevnar 20 serotypes plus 11 additional serotypes.
-

Eli Lilly’s Jaypirca Wins FDA Approval for First-Line CLL/SLL
The noncovalent BTK inhibitor reduced the risk of progression or death by 80% versus bendamustine plus rituximab in previously untreated patients without known del(17p). Key Takeaways Data Snapshot Item Details Company Eli Lilly Drug Jaypirca (pirtobrutinib) FDA approval date October 2, 2026 Indication Previously untreated adult CLL/SLL without known del(17p) Pivotal trial Phase 3 BRUIN…
